Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Company Profile Financials Financial Details

Financial Details

Highlights

Clarus Ventures has made 88 investments. Their most recent investment was on
obfuscation
, when Galera Therapeutics raised
obfuscation
.Clarus Ventures has raised 4 funds, their latest being Clarus IV-A. This fund was announced on
obfuscation
and raised a total of
obfuscation
.Clarus Ventures has made 15 diversity investments. Their most recent diversity investment was on
obfuscation
, when Cleave Therapeutics raised
obfuscation
.Clarus Ventures has had
obfuscation
exit, which was MacroGenics. Clarus Ventures has had
obfuscation
exits. Clarus Ventures's most notable exits include MacroGenics, Astria Therapeutics, and  Heptares Therapeutics.
Lead Investments 38
Investments 88
Exits 
obfuscation
Funds 4

M&A Details

Clarus Ventures was acquired by Blackstone Group on
obfuscation
.
Transaction Name 
Clarus Ventures acquired by Blackstone Group Logo
Clarus Ventures acquired by Blackstone Group
Acquired by 
Blackstone Group Logo
Blackstone Group
Announced Date 
obfuscation

Investments

Number of Portfolio Organizations 45
Number of Investments 88
Clarus Ventures has made 88 investments. Their most recent investment was on
obfuscation
, when Galera Therapeutics raised
obfuscation
.
How many investments has this organization made over time?
Which industries has this organization most actively invested in?
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Galera Therapeutics Logo
Galera Therapeutics
Yes
Series C - Galera Therapeutics Logo
Series C - Galera Therapeutics
obfuscation
obfuscation
Galera Therapeutics Logo
Galera Therapeutics
Yes
Series C - Galera Therapeutics Logo
Series C - Galera Therapeutics
obfuscation
obfuscation
Galera Therapeutics Logo
Galera Therapeutics
Yes
Series C - Galera Therapeutics Logo
Series C - Galera Therapeutics
obfuscation
obfuscation
Galera Therapeutics Logo
Galera Therapeutics
Yes
Series C - Galera Therapeutics Logo
Series C - Galera Therapeutics
obfuscation
obfuscation
Galera Therapeutics Logo
Galera Therapeutics
Yes
Series C - Galera Therapeutics Logo
Series C - Galera Therapeutics
obfuscation

Funds Raised

Number of Funds 4
Clarus Ventures has raised 4 funds, their latest being Clarus IV-A. This fund was announced on
obfuscation
and raised a total of
obfuscation
.
Announced Date  
Fund Name  
Money Raised  
obfuscation
Clarus IV-A Logo
Clarus IV-A
obfuscation
obfuscation
Clarus Lifesciences III Logo
Clarus Lifesciences III
obfuscation
obfuscation
Clarus Lifesciences II L.P. Logo
Clarus Lifesciences II L.P.
obfuscation
obfuscation
Clarus Lifesciences I L.P. Logo
Clarus Lifesciences I L.P.
obfuscation

Diversity Investments

Number of Diversity Investments 15
Clarus Ventures has made 15 diversity investments. Their most recent diversity investment was on
obfuscation
, when Cleave Therapeutics raised
obfuscation
.
Announced Date  
Organization Name  
Diversity Spotlight  
Funding Round  
Money Raised  
obfuscation
Cleave Therapeutics Logo
Cleave Therapeutics
Women Led
Series B - Cleave Therapeutics Logo
Series B - Cleave Therapeutics
obfuscation
obfuscation
GrayBug Logo
GrayBug
Women Founded
Series B - GrayBug Logo
Series B - GrayBug
obfuscation
obfuscation
Astria Therapeutics Logo
Astria Therapeutics
Women Founded, Women Led
Series B - Astria Therapeutics Logo
Series B - Astria Therapeutics
obfuscation
obfuscation
NanoString Technologies Logo
NanoString Technologies
Women Founded
Venture Round - NanoString Technologies Logo
Venture Round - NanoString Technologies
obfuscation
obfuscation
Astria Therapeutics Logo
Astria Therapeutics
Women Founded, Women Led
Venture Round - Astria Therapeutics Logo
Venture Round - Astria Therapeutics
obfuscation
obfuscation
NanoString Technologies Logo
NanoString Technologies
Women Founded
Series E - NanoString Technologies Logo
Series E - NanoString Technologies
obfuscation
obfuscation
Astria Therapeutics Logo
Astria Therapeutics
Women Founded, Women Led
Series A - Astria Therapeutics Logo
Series A - Astria Therapeutics
obfuscation
obfuscation
Cleave Therapeutics Logo
Cleave Therapeutics
Women Led
Series A - Cleave Therapeutics Logo
Series A - Cleave Therapeutics
obfuscation
obfuscation
NanoString Technologies Logo
NanoString Technologies
Women Founded
Series D - NanoString Technologies Logo
Series D - NanoString Technologies
obfuscation
obfuscation
Astria Therapeutics Logo
Astria Therapeutics
Women Founded, Women Led
Series A - Astria Therapeutics Logo
Series A - Astria Therapeutics
obfuscation

Exits

Number of Exits 
obfuscation
Clarus Ventures has had
obfuscation
exit, which was MacroGenics. Clarus Ventures has had
obfuscation
exits. Clarus Ventures's most notable exits include MacroGenics, Astria Therapeutics, and  Heptares Therapeutics.
Which industries has this organization had the most exits in?
MacroGenics Logo
MacroGenicsMacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases.
Astria Therapeutics Logo
Astria TherapeuticsAstria Therapeutics develops therapies for allergic and immunologic diseases.
Heptares Therapeutics Logo
Heptares TherapeuticsHeptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Imago BioSciences Logo
Imago BioSciencesImago is a clinical stage biopharmaceutical company that develops drugs for the management of proliferative diseases of the bone marrow.
NanoString Technologies Logo
NanoString TechnologiesNanoString Technologies provides a life science tools platform for a variety of basic research, translational medicine and IVD applications.
Annexon Biosciences Logo
Annexon BiosciencesAnnexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Galera Therapeutics Logo
Galera TherapeuticsGalera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
IVERIC bio Logo
IVERIC bioIVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Gritstone bio Logo
Gritstone bioGritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.
ESSA Pharma Logo
ESSA PharmaESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(05b78c5 1)
|